Bioprosthetic heart valve replacement: cumulative experience of 3 cardiac surgery centers in Russia

Автор: Barbarash L.S., Karaskov A.M., Semenovsky M.L., Juravleva I.J., Odarenko J.N., Vavilov P.A., Nokhrin A.V., Astapov D.A.

Журнал: Патология кровообращения и кардиохирургия @journal-meshalkin

Рубрика: Приобретенные пороки сердца

Статья в выпуске: 2 т.15, 2011 года.

Бесплатный доступ

We analysed log-term results of mitral (MVR), tricuspid (TVR) and aortic (AVR) valve replacement with epoxy-treated bioprostheses «KemCor» and «PeriCor» (965 patients, undergone surgery in 1991 -2005). Age younger than 18 was an exclusion criterion. All in all, there were 1047 implantations: 713 (68%) MVR, 315 (30%) TVR, 19 (2%) AVR. Average follow-up time was 4.1 years. Actuarial survival in 9 year of follow-up was 70%, freedom od reoperation due to prosthetic valve dysfunction was 60%. Dominant causes of dysfunction were prosthetic endocarditis (52%), primary tissue deterioration with calcification (19.6%) and the one with calcification (18.5%). Evident differences between the centers in complication rate and structure referred mainly to different approaches towards usage of bioprosthetic valves: inaccuracies in postoperative patient management at outpatient clinics are shown to negatively affect the long-term results. According to this, we see the necessity of National Standards development the for management of patients with implanted bioprosthetic heart valves.

Еще

Bioprosthesis, tissue valve, bioprosthetic dysfunctions

Короткий адрес: https://sciup.org/142140405

IDR: 142140405

Статья научная